Equities analysts predict that Seattle Genetics, Inc. (NASDAQ:SGEN) will post earnings of ($0.46) per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Seattle Genetics’ earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.55). Seattle Genetics posted earnings per share of ($0.39) in the same quarter last year, which would suggest a negative year-over-year growth rate of 17.9%. The company is expected to report its next quarterly earnings report after the market closes on Thursday, February 8th.
On average, analysts expect that Seattle Genetics will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.01) to ($0.84). For the next year, analysts anticipate that the firm will report earnings of ($1.34) per share, with EPS estimates ranging from ($1.76) to ($0.09). Zacks’ EPS calculations are an average based on a survey of research firms that follow Seattle Genetics.
Seattle Genetics (NASDAQ:SGEN) last posted its earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Seattle Genetics had a negative return on equity of 32.41% and a negative net margin of 26.53%. The business had revenue of $135.29 million during the quarter, compared to analyst estimates of $112.76 million. During the same quarter last year, the firm earned ($0.23) earnings per share. The company’s revenue for the quarter was up 27.3% compared to the same quarter last year.
Seattle Genetics (SGEN) traded up $0.03 during mid-day trading on Wednesday, hitting $53.48. The stock had a trading volume of 1,287,841 shares, compared to its average volume of 722,693. Seattle Genetics has a fifty-two week low of $45.31 and a fifty-two week high of $71.32. The firm has a market capitalization of $7,692.97, a price-to-earnings ratio of -62.19 and a beta of 2.37.
In other Seattle Genetics news, CFO Todd E. Simpson sold 39,385 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $60.91, for a total transaction of $2,398,940.35. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Vaughn B. Himes sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $59.97, for a total value of $599,700.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 157,210 shares of company stock worth $9,094,911. 34.70% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Seattle Genetics by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 7,530,515 shares of the biotechnology company’s stock worth $389,628,000 after purchasing an additional 167,828 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Seattle Genetics by 2.6% in the 2nd quarter. BlackRock Inc. now owns 7,453,483 shares of the biotechnology company’s stock worth $385,644,000 after purchasing an additional 185,823 shares during the last quarter. Capital International Investors lifted its holdings in shares of Seattle Genetics by 63.7% in the 3rd quarter. Capital International Investors now owns 4,460,246 shares of the biotechnology company’s stock worth $242,682,000 after purchasing an additional 1,735,657 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in shares of Seattle Genetics in the 3rd quarter worth approximately $140,098,000. Finally, Matrix Capital Management Company LP lifted its holdings in shares of Seattle Genetics by 18.8% in the 2nd quarter. Matrix Capital Management Company LP now owns 2,118,000 shares of the biotechnology company’s stock worth $109,585,000 after purchasing an additional 335,000 shares during the last quarter. 98.89% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/01/20/1713787.html.
Seattle Genetics Company Profile
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.